Abnormal Activity of the MAPK- and cAMP-Associated Signaling Pathways in Frontal Cortical Areas in Postmortem Brain in Schizophrenia
暂无分享,去创建一个
Vahram Haroutunian | V. Haroutunian | A. Funk | J. Meador-Woodruff | R. Mccullumsmith | Adam J Funk | Robert E McCullumsmith | James H Meador-Woodruff
[1] H. Corrêa,et al. The leukocytes expressing DARPP-32 are reduced in patients with schizophrenia and bipolar disorder , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[2] Brian O. Smith,et al. EPAC proteins transduce diverse cellular actions of cAMP , 2009, British journal of pharmacology.
[3] J. Crandall,et al. Cdk5 Regulates the Phosphorylation of Tyrosine 1472 NR2B and the Surface Expression of NMDA Receptors , 2008, The Journal of Neuroscience.
[4] V. Haroutunian,et al. Evidence for Abnormal Forward Trafficking of AMPA Receptors in Frontal Cortex of Elderly Patients with Schizophrenia , 2010, Neuropsychopharmacology.
[5] D. Surmeier,et al. Kalirin-7 Controls Activity-Dependent Structural and Functional Plasticity of Dendritic Spines , 2007, Neuron.
[6] Eric Klann,et al. Activation of exchange protein activated by cyclic-AMP enhances long-lasting synaptic potentiation in the hippocampus. , 2008, Learning & memory.
[7] V. Pawlak,et al. Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors , 2007, Neuropharmacology.
[8] K. Fukunaga,et al. Enhanced activation of Ca2+/Calmodulin‐dependent protein kinase II upon downregulation of cyclin‐dependent kinase 5‐p35 , 2006, Journal of neuroscience research.
[9] T. Asada,et al. Immunohistochemical and immunoblot analysis of Dopamine and cyclic AMP-regulated phosphoprotein, relative molecular mass 32,000 (DARPP-32) in the prefrontal cortex of subjects with schizophrenia and bipolar disorder , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[10] Philip D. Harvey,et al. The Course of Neuropsychological Performance and Functional Capacity in Older Patients with Schizophrenia: Influences of Previous History of Long-Term Institutional Stay , 2010, Biological Psychiatry.
[11] J. Sweatt,et al. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory , 2001, Journal of neurochemistry.
[12] M. Luca,et al. Dual role of CaMKII‐dependent SAP97 phosphorylation in mediating trafficking and insertion of NMDA receptor subunit NR2A , 2007, Journal of neurochemistry.
[13] Guang-yi Zhang,et al. PSD-95 promotes CaMKII-catalyzed serine phosphorylation of the synaptic RAS-GTPase activating protein SynGAP after transient brain ischemia in rat hippocampus , 2004, Brain Research.
[14] J. Meador-Woodruff,et al. Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia , 2008, Schizophrenia Research.
[15] R. Huganir,et al. Rapid and bi-directional regulation of AMPA receptor phosphorylation and trafficking by JNK , 2008, The EMBO journal.
[16] V. Haroutunian,et al. Variations in differential gene expression patterns across multiple brain regions in schizophrenia , 2005, Schizophrenia Research.
[17] A. Reichenberg,et al. The assessment of neuropsychological functioning in schizophrenia , 2010, Dialogues in clinical neuroscience.
[18] B. Burke,et al. Altered expression and coregulation of dopamine signalling genes in schizophrenia and bipolar disorder , 2011, Neuropathology and applied neurobiology.
[19] Y. Ip,et al. Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. , 1998, Current opinion in cell biology.
[20] R. Huganir,et al. Intracellular Modulation of NMDA Receptor Function by Antipsychotic Drugs , 2000, The Journal of Neuroscience.
[21] V. Haroutunian,et al. Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia , 2006, Molecular Psychiatry.
[22] R. Murray,et al. PAGES_DCNS 46_5.qxd:DCNS#45 , 2010 .
[23] J. Meador-Woodruff,et al. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder , 2001, Brain Research Bulletin.
[24] K. Tang,et al. Spatial and Temporal Regulation of RACK1 Function and N-methyl-D-aspartate Receptor Activity through WD40 Motif-mediated Dimerization* , 2004, Journal of Biological Chemistry.
[25] J. Sweatt,et al. Mitogen-activated protein kinases in synaptic plasticity and memory , 2004, Current Opinion in Neurobiology.
[26] G. Rosenbaum,et al. Study of a new schizophrenomimetic drug; sernyl. , 1959, A.M.A. archives of neurology and psychiatry.
[27] K. Davies,et al. Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices , 2009, Neuroscience.
[28] N. Ip,et al. Integration of Signals from Receptor Tyrosine Kinases and G Protein-Coupled Receptors , 2002, Neurosignals.
[29] D. Purpura,et al. NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders , 2007, Nature Reviews Neuroscience.
[30] L. Tsai,et al. Reelin and Cyclin-Dependent Kinase 5-Dependent Signals Cooperate in Regulating Neuronal Migration and Synaptic Transmission , 2004, The Journal of Neuroscience.
[31] Y. Ben-Ari,et al. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal‐regulated kinases (ERK) activity in cultured rat hippocampal neurons , 2006, The Journal of physiology.
[32] A. Elbein,et al. Increased Expression of c-Jun Transcription Factor in Cerebellar Vermis of Patients with Schizophrenia , 2003, Neuropsychopharmacology.
[33] G. Winterer,et al. The Molecular and Cellular Neurobiology of Nicotine Abuse in Schizophrenia , 2008, Pharmacopsychiatry.
[34] Angus W MacDonald,et al. What we know: findings that every theory of schizophrenia should explain. , 2009, Schizophrenia bulletin.
[35] D. Hochbaum,et al. Epac, in Synergy with cAMP-dependent Protein Kinase (PKA), Is Required for cAMP-mediated Mitogenesis* , 2008, Journal of Biological Chemistry.
[36] R. Huganir,et al. Characterization of Protein Kinase A and Protein Kinase C Phosphorylation of the N-Methyl-D-aspartate Receptor NR1 Subunit Using Phosphorylation Site-specific Antibodies* , 1997, The Journal of Biological Chemistry.
[37] A. Bonci,et al. NMDA receptor function is regulated by the inhibitory scaffolding protein, RACK1 , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[38] V. Haroutunian,et al. Altered Vesicular Glutamate Transporter Expression in the Anterior Cingulate Cortex in Schizophrenia , 2008, Biological Psychiatry.
[39] J.F.W. Deakin,et al. Neurobiology of schizophrenia , 1996 .
[40] L. Tsai,et al. Cyclin-Dependent Kinase 5 Phosphorylates the N-Terminal Domain of the Postsynaptic Density Protein PSD-95 in Neurons , 2004, The Journal of Neuroscience.
[41] Angus C Nairn,et al. DARPP-32: an integrator of neurotransmission. , 2004, Annual review of pharmacology and toxicology.
[42] M. Sheng,et al. Synaptic Accumulation of PSD-95 and Synaptic Function Regulated by Phosphorylation of Serine-295 of PSD-95 , 2007, Neuron.
[43] V. Haroutunian,et al. Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia , 2010, Schizophrenia Research.
[44] M. di Luca,et al. Calcium–calmodulin‐dependent protein kinase II phosphorylation modulates PSD‐95 binding to NMDA receptors , 2006, The European journal of neuroscience.
[45] R. Davis,et al. Signal transduction by the c-Jun N-terminal kinase. , 1999, Biochemical Society symposium.
[46] M. Laruelle,et al. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. , 2003, Annals of the New York Academy of Sciences.
[47] D R Medoff,et al. Ketamine activates psychosis and alters limbic blood flow in schizophrenia , 1995, Neuroreport.
[48] R. Duncan,et al. Specific Targeting of Pro-Death NMDA Receptor Signals with Differing Reliance on the NR2B PDZ Ligand , 2008, The Journal of Neuroscience.
[49] J. Zhu,et al. Rap2-JNK Removes Synaptic AMPA Receptors during Depotentiation , 2005, Neuron.
[50] V. Haroutunian,et al. Expression of the NR2B‐NMDA receptor subunit and its Tbr‐1/CINAP regulatory proteins in postmortem brain suggest altered receptor processing in schizophrenia , 2010, Synapse.
[51] P. Dutar,et al. The magnitude of hippocampal long term depression depends on the synaptic location of activated NR2-containing N-methyl-d-aspartate receptors , 2008, Neuroscience.
[52] J. Meador-Woodruff,et al. NMDA receptors and schizophrenia. , 2007, Current opinion in pharmacology.
[53] Carol A. Tamminga,et al. Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.
[54] Jürgen Gallinat,et al. Molecular Mechanisms of Schizophrenia , 2007, Cellular Physiology and Biochemistry.
[55] V. Haroutunian,et al. Expression of four housekeeping proteins in elderly patients with schizophrenia , 2009, Journal of Neural Transmission.
[56] Chia-Hsiang Chen,et al. Genetic and Functional Analysis of the DLG4 Gene Encoding the Post-Synaptic Density Protein 95 in Schizophrenia , 2010, PloS one.
[57] D. Choquet,et al. Surface trafficking of N-methyl-d-aspartate receptors: Physiological and pathological perspectives , 2009, Neuroscience.
[58] P. Greengard,et al. Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation , 2007, Nature Neuroscience.
[59] D. Volk,et al. Alterations in metabotropic glutamate receptor 1α and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia. , 2010, The American journal of psychiatry.
[60] Xiaodong Cheng,et al. Epac and PKA: a tale of two intracellular cAMP receptors. , 2008, Acta biochimica et biophysica Sinica.
[61] J. Kennedy,et al. Reduced prefrontal cortex DARPP-32 mRNA in completed suicide victims with schizophrenia , 2008, Schizophrenia Research.
[62] C. Karson,et al. Increased levels of transcription factors Elk-1, cyclic adenosine monophosphate response element-binding protein, and activating transcription factor 2 in the cerebellar vermis of schizophrenic patients. , 2000, Archives of General Psychiatry.
[63] TylerZARUBIN,et al. Activation and signaling of the p38 MAP kinase pathway , 2005 .
[64] M. Karayiorgou,et al. Decreased Phosphorylation of NMDA Receptor Type 1 at Serine 897 in Brains of Patients with Schizophrenia , 2004, The Journal of Neuroscience.
[65] K. Dalby,et al. Haloperidol and Clozapine Differentially Affect the Expression of Arrestins, Receptor Kinases, and Extracellular Signal-Regulated Kinase Activation , 2008, Journal of Pharmacology and Experimental Therapeutics.
[66] G. Rumbaugh,et al. Decreased expression of NMDA receptor-associated proteins in frontal cortex of elderly patients with schizophrenia , 2009, Neuroreport.
[67] S. Arnold,et al. AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs , 2007, Schizophrenia Research.
[68] David G Standaert,et al. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. , 2004, Molecular pharmacology.
[69] S. Kyosseva. Mitogen-activated protein kinase signaling. , 2004, International review of neurobiology.
[70] R. Huganir,et al. MINK and TNIK Differentially Act on Rap2-Mediated Signal Transduction to Regulate Neuronal Structure and AMPA Receptor Function , 2010, The Journal of Neuroscience.
[71] M. Karin,et al. c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases , 1994, Molecular and cellular biology.
[72] H. Manji,et al. Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. , 2010, Journal of affective disorders.
[73] P. Greengard,et al. Diverse Psychotomimetics Act Through a Common Signaling Pathway , 2003, Science.
[74] David M. Santucci,et al. The Effects of NR2 Subunit-Dependent NMDA Receptor Kinetics on Synaptic Transmission and CaMKII Activation , 2008, PLoS Comput. Biol..
[75] H. Bading,et al. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders , 2010, Nature Reviews Neuroscience.
[76] E. Choi,et al. Pathological roles of MAPK signaling pathways in human diseases. , 2010, Biochimica et biophysica acta.
[77] J. Kleinman,et al. Psychiatric Brain Banking: Three Perspectives on Current Trends and Future Directions , 2011, Biological Psychiatry.
[78] J. Meador-Woodruff,et al. Glutamate receptor expression in schizophrenic brain , 2000, Brain Research Reviews.
[79] C. Tamminga,et al. Effects of Ketamine in Normal and Schizophrenic Volunteers , 2001, Neuropsychopharmacology.
[80] V. Haroutunian,et al. mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics , 2005, Journal of neuroscience research.
[81] J. Kennedy,et al. Genetics in schizophrenia: where are we and what next? , 2010, Dialogues in clinical neuroscience.
[82] F. Fumagalli,et al. Antipsychotic drug actions on gene modulation and signaling mechanisms. , 2009, Pharmacology & therapeutics.
[83] Philip D. Harvey,et al. Assessment of dementia in elderly schizophrenics with structured rating scales , 1992, Schizophrenia Research.
[84] T. Palmer,et al. Regulating gene transcription in response to cyclic AMP elevation. , 2008, Cellular signalling.
[85] H. Chi,et al. Regulation of JNK and p38 MAPK in the immune system: signal integration, propagation and termination. , 2009, Cytokine.
[86] H. Wright,et al. Phencyclidine-induced psychosis. , 1980, Southern medical journal.
[87] Vahram Haroutunian,et al. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: A gene ontology study , 2005, Schizophrenia Research.
[88] K. Mikoshiba,et al. Modulation of Reelin signaling by Cyclin-dependent kinase 5 , 2007, Brain Research.
[89] Svetlana V. Kyosseva,et al. Differential expression of mitogen-activated protein kinases and immediate early genes fos and jun in thalamus in schizophrenia , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[90] M. Bogoyevitch,et al. c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. , 2010, Biochimica et biophysica acta.
[91] V. Haroutunian,et al. Dopamine receptor signaling molecules are altered in elderly schizophrenic cortex , 2006, Synapse.
[92] M. Lyon,et al. Mitogen-activated protein kinases in schizophrenia , 1999, Biological Psychiatry.
[93] E. Wagner,et al. Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.
[94] K. Davis,et al. Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: involvement of the intracellular signal integrating proteins calcyon and spinophilin. , 2005, The American journal of psychiatry.
[95] M. Ahmadian,et al. The C2 domain of SynGAP is essential for stimulation of the Rap GTPase reaction , 2008, EMBO reports.
[96] P. Calabresi,et al. Decreased NR2B Subunit Synaptic Levels Cause Impaired Long-Term Potentiation But Not Long-Term Depression , 2009, The Journal of Neuroscience.
[97] T. Hashimoto,et al. Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons. , 2007, International review of neurobiology.
[98] J. Sweatt,et al. The Mitogen-Activated Protein Kinase Cascade Couples PKA and PKC to cAMP Response Element Binding Protein Phosphorylation in Area CA1 of Hippocampus , 1999, The Journal of Neuroscience.
[99] K. Davis,et al. Postmortem studies in schizophrenia , 2000, Schizophrenia bulletin.
[100] M. Laruelle,et al. Glutamate, Dopamine, and Schizophrenia , 2003 .
[101] Karen Faith Berman,et al. Executive Function, Neural Circuitry, and Genetic Mechanisms in Schizophrenia , 2010, Neuropsychopharmacology.
[102] R. Siegel,et al. Association of PSD‐95 with ErbB4 facilitates neuregulin signaling in cerebellar granule neurons in culture , 2007, Journal of neurochemistry.
[103] T. Abel,et al. Exchange protein activated by cAMP enhances long-term memory formation independent of protein kinase A. , 2009, Learning & memory.
[104] Philip D. Harvey,et al. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. , 1995, The American journal of psychiatry.
[105] H. Bading,et al. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways , 2002, Nature Neuroscience.
[106] R. Anwyl,et al. Extrasynaptic NR2D-Containing NMDARs Are Recruited to the Synapse during LTP of NMDAR-EPSCs , 2008, The Journal of Neuroscience.
[107] Kari Stefansson,et al. Neuregulin1 (NRG1) Signaling through Fyn Modulates NMDA Receptor Phosphorylation: Differential Synaptic Function in NRG1+/− Knock-Outs Compared with Wild-Type Mice , 2007, The Journal of Neuroscience.
[108] Paul Greengard,et al. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. , 2002, Archives of general psychiatry.
[109] D. Clapham,et al. SynGAP-MUPP1-CaMKII Synaptic Complexes Regulate p38 MAP Kinase Activity and NMDA Receptor- Dependent Synaptic AMPA Receptor Potentiation , 2004, Neuron.
[110] S. Akbarian,et al. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders , 2006, Brain Research Reviews.
[111] David A Lewis,et al. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. , 2006, Archives of neurology.
[112] Georg Winterer,et al. Why do patients with schizophrenia smoke? , 2010, Current opinion in psychiatry.
[113] S. Fatemi,et al. The neurodevelopmental hypothesis of schizophrenia, revisited. , 2009, Schizophrenia bulletin.